Investing.com - Bio-Rad Labs (NYSE: BIO) reported second quarter EPS of $3.11, $1.10 better than the analyst estimate of $2.01. Revenue for the quarter came in at $638.5M versus the consensus estimate of $645.79M.
Guidance
Bio-Rad Labs sees Q3 2024 revenue of $638.50M-$681.10M versus the analyst consensus of $661.00M.
Bio-Rad Labs's stock price closed at $341.25. It is up 21.95% in the last 3 months and down -15.48% in the last 12 months.
Bio-Rad Labs saw 1 positive EPS revisions and 3 negative EPS revisions in the last 90 days. See Bio-Rad Labs's stock price’s past reactions to earnings here.
According to InvestingPro, Bio-Rad Labs's Financial Health score is "good performance".
Check out Bio-Rad Labs's recent earnings performance, and Bio-Rad Labs's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar